Lumira Ventures is proud to share that Kevin Eisenfrats, Co-Founder and CEO of portfolio company Contraline, Inc., was recently featured in a UBS interview discussing the company’s mission to redefine reproductive health for men and couples worldwide.
Contraline, a clinical-stage biopharmaceutical company, is advancing two investigational male contraceptive candidates: NES/T Gel, a once-daily, hormonal, reversible topical gel developed in collaboration with the Population Council and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and ADAM™, a long-lasting, non-hormonal, reversible hydrogel implant. Together, these programs represent one of the most advanced pipelines in a field that has seen no major innovation in over a century.
“Male contraception represents one of the largest unmet needs in reproductive health,” said Kevin Eisenfrats. “Our mission at Contraline is to create new contraceptive options that expand reproductive choice for men and couples.”
Watch the full interview: 2026 UBS Contraline Interview